Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 5/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7741693 | 0.80 | CDK5 (0.42) | SRD5A1SRD5A2GRIN1GRIN2BCDK5 | |
| SCHEMBL8713486 | 0.79 | SRD5A1 (0.41) | SRD5A1SRD5A2GRIN1GRIN2B | |
| SCHEMBL1552900 | 0.78 | SRD5A1 (0.52) | SRD5A1SRD5A2 | |
| SCHEMBL4729969 | 0.78 | SRD5A1 (0.52) | SRD5A1SRD5A2 | |
| SCHEMBL5596630 | 0.78 | SRD5A1 (0.52) | SRD5A1SRD5A2 | |
| SCHEMBL8076029 | 0.77 | NR1I3 (0.47) | GRIN1GRIN2BCDK5CDK5R1NR1I3 | |
| SCHEMBL9620174 | 0.74 | SRD5A2 (0.42) | SRD5A1SRD5A2GRIN1GRIN2BCDK5 | |
| SCHEMBL7711773 | 0.72 | GRIN1 (0.40) | GRIN1GRIN2BCDK5CDK5R1NR1I3 | |
| SCHEMBL7617440 | 0.71 | SRD5A1 (0.61) | SRD5A1SRD5A2 | |
| SCHEMBL7617435 | 0.71 | SRD5A1 (0.61) | SRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6046183-A | SYNERGISTIC MIXTURE OF FINASTERIDE AND DOXAZOSIN | MERCK & CO., INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5994362-A | ADMINISTERING FINASTERIDE AND CASODEX | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5753641-A | SYNERGISTIC THERAPY COMPRISING FINASTERIDE AND TERAZOSIN DRUGS | MERCK & CO., INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0674521-A4 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17-g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5-g(a)-ANDROST-1-EN-3-ONES. | MERCK & CO INC (US) | 1998-02-04 | — | — | EP | disclosed |
| EP-0547691-B1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0674521-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17$g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5$g(a)-ANDROST-1-EN-3-ONES | MERCK & CO. INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014452-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17β-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0547687-A1 | 17B-N-Substituted adamantyl/norbonanyl carbamoyl-4-aza-5a-and-rost-1-en-3-ones and androstan-3 ones | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992016213-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016233-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC CANCER CONTAINING A 5 ALPHA REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0462662-A2 | 17beta-N-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |